Alveolar macrophages as orchestrators of COPD
- PMID: 16997739
- DOI: 10.1081/COPD-120028701
Alveolar macrophages as orchestrators of COPD
Abstract
Alveolar macrophages play a critical role in the pathophysiology of COPD and are a major target for future anti-inflammatory therapy. Macrophage numbers are markedly increased in the lung and alveolar space of patients with COPD and are localized to sites of alveolar destruction. The increased numbers of macrophages may result from increased recruitment of blood monocytes, prolonged survival in the lung and to a lesser extent to increased proliferation in the lung. Alveolar macrophages from COPD patients have an increased baseline and stimulated secretion of inflammatory proteins, including certain cytokines, chemokines, reactive oxygen species and elastolytic enzymes, which together could account for all of the pathophysiological features of COPD. Alveolar macrophages form COPD appear to be resistant to the anti-inflammatory effects of corticosteriods and this is linked to reduced activity and expression of histone deacetylase 2, a nuclear enzyme that switches off inflammatory genes activated through the transcription factor nuclear factor-KB. Alternative anti-inflammatory therapies that inhibit macrophages are therefore needed in the future to deal with the chronic inflammation of COPD. These drugs may include resveratrol, theophylline derivatives, MAP kinase inhibitors and phosphodiesterase-4 inhibitors.
Similar articles
-
Alveolar macrophages in chronic obstructive pulmonary disease (COPD).Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL627-37. Cell Mol Biol (Noisy-le-grand). 2004. PMID: 15579256 Review.
-
Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2.J Leukoc Biol. 2004 Aug;76(2):441-50. doi: 10.1189/jlb.1003495. Epub 2004 May 20. J Leukoc Biol. 2004. PMID: 15155777
-
Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease.Basic Clin Pharmacol Toxicol. 2011 Aug;109(2):138-43. doi: 10.1111/j.1742-7843.2011.00707.x. Epub 2011 May 6. Basic Clin Pharmacol Toxicol. 2011. PMID: 21447053
-
Corticosteroids: the drugs to beat.Eur J Pharmacol. 2006 Mar 8;533(1-3):2-14. doi: 10.1016/j.ejphar.2005.12.052. Epub 2006 Jan 24. Eur J Pharmacol. 2006. PMID: 16436275 Review.
-
Epigenetic regulation of airway inflammation.Curr Opin Immunol. 2007 Dec;19(6):694-700. doi: 10.1016/j.coi.2007.07.016. Epub 2007 Aug 27. Curr Opin Immunol. 2007. PMID: 17720468 Review.
Cited by
-
Inflammation mechanism and research progress of COPD.Front Immunol. 2024 Aug 9;15:1404615. doi: 10.3389/fimmu.2024.1404615. eCollection 2024. Front Immunol. 2024. PMID: 39185405 Free PMC article. Review.
-
Structurally Related Monoterpenes p-Cymene, Carvacrol and Thymol Isolated from Essential Oil from Leaves of Lippia sidoides Cham. (Verbenaceae) Protect Mice against Elastase-Induced Emphysema.Molecules. 2016 Oct 20;21(10):1390. doi: 10.3390/molecules21101390. Molecules. 2016. PMID: 27775634 Free PMC article.
-
Protein kinase C zeta mediates cigarette smoke/aldehyde- and lipopolysaccharide-induced lung inflammation and histone modifications.J Biol Chem. 2010 Feb 19;285(8):5405-16. doi: 10.1074/jbc.M109.041418. Epub 2009 Dec 11. J Biol Chem. 2010. PMID: 20007975 Free PMC article.
-
Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease.Respir Res. 2006 Oct 25;7(1):133. doi: 10.1186/1465-9921-7-133. Respir Res. 2006. PMID: 17064412 Free PMC article.
-
Lung emphysema and impaired macrophage elastase clearance in mucolipin 3 deficient mice.Nat Commun. 2022 Jan 14;13(1):318. doi: 10.1038/s41467-021-27860-x. Nat Commun. 2022. PMID: 35031603 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
